ANTIMICROBIAL CHOICE PROTOCOLS IN PATIENTS WITH BETA-LACTAM RESISTANCE: AN INTEGRATIVE REVIEW
DOI:
https://doi.org/10.61164/tpbnqa50Keywords:
Beta-Lactams, Clinical Protocols, Antimicrobial ResistanceAbstract
Beta-lactam antibiotics are commonly used in the treatment of infections, especially in hospital settings, where their effectiveness depends on maintaining plasma concentrations above the minimum inhibitory concentration. Factors such as comorbidities, bacterial resistance, and allergic reactions compromise the efficacy and safety of these drugs, leading to possible resistance, mainly in bacteria that produce extended-spectrum beta-lactamases (ESBLs), which reduces therapeutic options. Thus, this study aimed to present protocols for choosing antimicrobials for patients with beta-lactam resistance. The data search in this study is based on a descriptive, integrative review with an explanatory character, adopting a qualitative approach. It was conducted in the scientific databases PubMed, BVS, and SciELO, using the health descriptors registered in DeCS/MeSH: "Beta-Lactams," "Clinical Protocols," and "Antimicrobial Resistance." To contribute to the research and the search for evidence, the PICO strategy will be adopted, including inclusion and exclusion criteria following the PRISMA protocol. The results conclude that the choice of a therapeutic protocol is crucial for clinical success and reducing treatment failures, making the inclusion of efficient management for the use of antimicrobials and the promotion of successful patient treatment inevitable.
Downloads
References
BOMFIM, I. M. F. N.; AMARAL, M. A.; RODRIGUES, Y. C.; BRASILIENSE, D. M.; AIRES, C. A. M.; NETO, R. M. Clones de alto risco de Klebsiella pneumoniae produtores de ESBL colonizando pacientes de UTI em Natal, Nordeste do Brasil. (2023). Revista De Epidemiologia E Controle De Infecção, v.13, n. 3, DOI: https://doi.org/10.17058/reci.v13i3.18307 DOI: https://doi.org/10.17058/reci.v13i3.18307
BRASIL. Ministério da Saúde. Protocolo Clínico E Diretrizes Terapêuticas Para Atenção Integral Às Pessoas Com Infecções Sexualmente Transmissíveis (IST). Brasília, DF: Ministério da Saúde, 2022. Disponível em: https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2022/ist/pcdt-ist-2022_isbn-1.pdf. Acesso em: 3 nov. 2025.
BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). Plano Nacional para Prevenção e Controle da Resistência aos Antimicrobianos em Serviços de Saúde. Brasília, DF: ANVISA, 2023. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/servicosdesaude/prevencao-e-controle-de-infeccao-e-resistencia-microbiana/pnpciras-e-pan-servicos-de-saude/pan-servicos-de-saude-2023-2027-final-15-12-2023.pdf. Acesso em: 3 nov. 2025.
BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). Diretriz Nacional para Elaboração de Programa de Gerenciamento de Antimicrobianos em Serviços de Saúde - Revisão. Brasília, DF: ANVISA, 2023. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/publicacoes/DiretrizGerenciamentoAntimicrobianosANVISA2023FINAL.pdf. Acesso em: 3 nov. 2025.
BRASIL. Fundação Oswaldo Cruz (FIOCRUZ). Superbactérias Resistentes a Antimicrobianos: Novo Livro Da Editora Fiocruz Alerta Sobre Ameaça Crescente À Saúde Pública. Rio de Janeiro, RJ: FIOCRUZ, 2025. Disponível em: https://fiocruz.br/noticia/2025/04/superbacterias-resistentes-antimicrobianos-novo-livro-da-editora-fiocruz-alerta#:~:text=Superbact%C3%A9rias%20Resistentes%20a%20Antimicrobianos:%20novo,%C3%A0%20sa%C3%BAde%20p%C3%BAblica%20%7C%20Portal%20Fiocruz. Acesso em: 3 nov. 2025.
BRASIL. Sociedade Brasileira de Infectologia (SBI). Recomendações para Tratamento e Prevenção de Infecções Causadas por Bacilos Gram-Negativos Multirresistentes. Sociedade Brasileira de Infectologia, 2024. Disponível em: https://infectologia.org.br/destaque/recomendacoes-para-tratamento-e-prevencao-de-infeccoes-causadas-por-bacilos-gram-negativos-multirresistentes/. Acesso em: 3 nov. 2025.
BRIGADOI, G.; LIBERATI, C.; GRES, E.; BARBIERI, E.; BOREGGIO, E.; ROSSIN, S.; TIRELLI, F.; TESSER, F.; CHIUSAROLI, L.; DEMARIN, G. C.; MAESTRI, L.; GIAQUINTO, C.; DA DALT, L.; BRESSAN, S.; DONÀ, D. Impact of an antibiotic stewardship program on adherence to antibiotic prescription in children admitted with urinary tract infection. Ther Adv Infect Disease. 2024 Oct 30;11:20499361241282824. DOI: 10.1177/20499361241282824. PMID: 39493726; PMCID: PMC11528598. DOI: https://doi.org/10.1177/20499361241282824
CUI, Y.; ZHANG, S.; HU, S.; FEI, S.; YANG, G. Efficacy of susceptibility-guided quadruple therapy with antibiotic resistance using the string test coupled with quantitative PCR for Helicobacter pylori eradication: a protocol of a multicentre, open, randomised clinical trial. BMJ Open. 2024 Dec 20;14(12):e088788. doi: 10.1136/bmjopen-2024-088788. PMID: 39806630; PMCID: PMC11667473. DOI: https://doi.org/10.1136/bmjopen-2024-088788
DARWISH MALIK, M.; DOW ALLISON, L.; DESAI, ANGEL N.; CATALAN MARINELL, I.; MCGLYNN, COLIN C.; SUHD-BRONDSTATTER, JENNIFER; KINGSLEY, AMY; WILSON, TIMOTHY; COHEN STUART, H.; REILLY MARY, E. Surto hospitalar de Acinetobacter baumannii resistente a carbapenêmicos no contexto de transmissão local em unidade de saúde. American Journal of Infection Control, v. 52, n. 6, p. 739-741, 2024. DOI: https://doi.org/10.1016/j.ajic.2024.01.011
FLEITAS, O.; REBOLLAR, E. A.; BUSTAMANTE, V. H. Extracellular defense of bacteria against antimicrobial peptides. J Bacteriol. 2025 Aug 21;207(8):e0016625. doi: 10.1128/jb.00166-25. Epub 2025 Aug 1. PMID: 40748075; PMCID: PMC12369334. DOI: https://doi.org/10.1128/jb.00166-25
GÁGYOR, I.; GRESER, A.; HEUSCHMANN, P.; RÜCKER, V.; MAUN, A.; BLEIDORN, J.; HEINTZE, C.; JEDE, F.; ECKMANNS, T.; KLINGEBERG, A.; MENTZEL, A.; SCHMIEMANN, G. REDuction of Antibiotic RESistance (REDARES) in urinary tract infections using treatments according to national clinical guidelines: study protocol for a pragmatic randomized controlled trial with a multimodal intervention in primary care. BMC Infect Dis. 2021 Sep 23;21(1):990. doi: 10.1186/s12879-021-06660-0. PMID: 34556027; PMCID: PMC8461906. DOI: https://doi.org/10.1186/s12879-021-06660-0
HORSTINK, M. M. B.; GEEL, D. R.; UIL, C. A. D.; DEETMAN, P. E.; ENDEMAN, H.; ABDULLA, A.; BOSCH, T. M.; RIETDIJK, W. J. R.; THIELEN, F. W.; HARINGMAN, J. J.; VAN VLIET, P.; RIJPSTRA, T. A.; BETHLEHEM, C.; BEISHUIZEN, A.; MULLER, A. E. & KOCH BCP BULLSEYE INVESTIGATORS. Standard versus double dosing of beta-lactam antibiotics in critically ill patients with sepsis: The BULLSEYE study protocol for a multicenter randomized controlled trial. BMC Infect Diseases. 2025 Mar 21;25(1):392. doi: 10.1186/s12879-025-10747-3. Erratum in: BMC Infect Dis. 2025 Apr 7;25(1):473. doi: 10.1186/s12879-025-10877-8. PMID: 40119275; PMCID: PMC11929207. DOI: https://doi.org/10.1186/s12879-025-10877-8
KARIYAWASAM, R. M.; JULIEN, D. A.; JELINSKI, D. C.; LAROSE, S. L.; RENNERT-MAY, E.; CONLY, J. M.; DINGLE, T. C.; CHEN, J. Z.; TYRRELL, G. J.; RONKSLEY, P. E.; BARKEMA, H. W. Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021). Antimicrob Resist Infect Control. 2022 Mar 7;11(1):45. doi: 10.1186/s13756-022-01085-z. PMID: 35255988; PMCID: PMC8899460. DOI: https://doi.org/10.1186/s13756-022-01085-z
KHADSE, S.; N.; UGEMUGE, S.; SINGH, C. Impact of Antimicrobial Stewardship on Reducing Antimicrobial Resistance. Cureus. 2023 Dec 4;15(12):e49935. doi: 10.7759/cureus.49935. PMID: 38179391; PMCID: PMC10765068. DOI: https://doi.org/10.7759/cureus.49935
LAPORTE-AMARGOS J.; GUDIOL C.; ARNAN M.; PUERTA-ALCALDE P.; CARMONA-TORRE F.; HUGUET M.; ALBASANZ-PUIG A.; PARODY R.; GARCIA-VIDAL C.; DEL POZO J.L.; BATLLE M.; TEBÉ C.; RIGO-BONNIN R.; MUÑOZ C., PADULLÉS A.; TUBAU F.; VIDELA S.; SUREDA A.; CARRATALÀ J. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Trials. v. 21, n. 1, p. 412, 2020. DOI: https://doi.org/10.1186/s13063-020-04323-0
LOAIZA, W. M.; RUIZ, A. K. R.; PATIÑO, C. C. O.; VIVAS, M. C. Bacterial Resistance in Hospital-Acquired Infections Acquired in the Intensive Care Unit: A Systematic Review. Acta Medica (Hradec Kralove). 2023;66(1):1-10. doi: 10.14712/18059694.2023.8. PMID: 37384803. DOI: https://doi.org/10.14712/18059694.2023.8
LUMKUL, L.; CHUAMANOCHAN, M.; NOCHAIWONG, S.; SOMPORNRATTANAPHAN, M.; KULALERT, P.; LAO-ARAYA, M.; WONGYIKUL, P.; PHINYO P. Genetic Association of Beta-Lactams-Induced Hypersensitivity Reactions: A Protocol for Systematic Review and Meta-Analysis. Genes (Basel), v. 13, n. 4, p. 681, 2022. DOI: https://doi.org/10.3390/genes13040681
MARCOS-CARBAJAL, P.; SALVATIERRA, G.; YARETA, J.; PINO J.; VÁSQUEZ N.; DIAZ P.; MARTÍNEZ I.; ASMAT P.; PERALTA C.; HUAMANI C.; BRIONES A.; RUIZ M.; LAURA N.; LUQUE Á.; ARAPA L.; TSUKAYAMA P. Caracterización microbiológica y molecular de la resistencia antimicrobiana de Escherichia coli uropatógenas de hospitales públicos peruanos. Revista peruana de medicina experimental y salud publica, v. 38, n. 1, p. 119–123, 2021. DOI: https://doi.org/10.17843/rpmesp.2021.381.6182
PAI MANGALORE, R.; CHAI, M.G.; POPE, J.; LEE, S.J.; PADIGLIONE, A.; DIEHL, A.; ROBERTS, L.; SIM, K.; RAWSON-HARRIS, P.; WICHA, S.; SCHNEIDER, H.G.; PEEL, T.N.; JENNEY, A.; AYTON, D.; PELEG, A.Y.; UDY, A.A.; Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring. BMJ Open, v. 14, n. 6, p. e083635, jun. 2024. DOI: https://doi.org/10.1136/bmjopen-2023-083635
RONDA, M.; PADULLÉS, A.; SIMONET, P.; RODRÍGUEZ, G.; ESTRADA, C.; LÉRIDA, A.; FERRO, J. J.; COBO, S.; TUBAU, F.; GARDEÑES, L.; FREIXEDAS, R.; LÓPEZ, M.; CARRERA, E.; PALLARÉS, N.; TEBE, C.; CARRATALA, J.; PUIG-ASENSIO, M.; SHAW, E. Infectious diseases experts as part of the antibiotic stewardship team in primary care: protocol for a cluster-randomised blinded study (IDASP). BMJ Open. 2021 Oct 11;11(10):e053160. doi: 10.1136/bmjopen-2021-053160. PMID: 34635529; PMCID: PMC8506866. DOI: https://doi.org/10.1136/bmjopen-2021-053160
SANTOS, G. DE O.; TEIXEIRA, R. S. Detection of carbapenem hydrolyzing enzyme and extended spectrum beta-lactamase in clinical isolates of Enterobacteriaceae and Pseudomonaceae. RBAC, v. 52, n. 3, 2020. DOI: https://doi.org/10.21877/2448-3877.202100919
URZEDO, J. E.; MENEZES, R. P.; PORTO, J. P.; FERREIRA, M. L.; GONÇALVES, I. R.; BRITO, C. S.; GONTIJO-FILHO, P. P.; RIBAS, R. M. High mortality by nosocomial infections caused by carbapenem-resistant Pseudomonas aeruginosa in a referral hospital in Brazil: facing the perfect storm. Journal of Medical Microbiology, v. 69, n. 12, 2020. DOI: 10.1099/jmm.0.001273. DOI: https://doi.org/10.1099/jmm.0.001273
VANEGAS, J. M.; SALAZAR-OSPINA, L.; MONTOYA-URREGO, D.; BUILES, J.; RONCANCIO, G. E.; JIMÉNEZ, J. N. High frequency of colonization by diverse clones of beta-lactam-resistant Gram-negative bacilli in haemodialysis: different sources of transmission outside the renal unit? Journal of Medical Microbiology, v. 69, n. 9, 2020. DOI: 10.1099/jmm.0.001244. DOI: https://doi.org/10.1099/jmm.0.001244
WU, X.; ZHONG, G.; WANG, H.; ZHU, J. Temporal association between antibiotic use and resistance in Gram-negative bacteria. Brazilian Journal of Biology, v. 83, p. e239323, 2023. DOI: https://doi.org/10.1590/1519-6984.239323
YASSARA, S.; ZEOUK, I.; JAOUHAR, S.; SBITI, M.; BEKHTI, K. Extended-spectrum beta-lactamases: definition, history, an update on their genetic environment and detection methods. J Med Microbiol. 2025 Jun;74(6):002033. doi: 10.1099/jmm.0.002033. PMID: 40554694; PMCID: PMC12188005. DOI: https://doi.org/10.1099/jmm.0.002033
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jean Carlos Rufino Mascelino Costa, Francisca Sabrina Vieira Lins, Ana Emília Formiga Marques, Rafaela de Oliveira Nóbrega
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
